Institut Bergonié
Bordeaux's dedicated cancer hospital, a UNICANCER centre known for sarcoma, early-phase trials and precision medicine.
Founded in 1923 and named after the radiobiologist Jean Bergonié, the Institut Bergonié is the UNICANCER comprehensive cancer centre for Nouvelle-Aquitaine. It is a national reference centre for sarcomas within the French Sarcoma Group and NetSarc network, and runs an early-phase trials unit that is part of INCa's CLIP² network. Research with Université de Bordeaux and Inserm covers sarcoma biology, tumour genomics and radiotherapy. Patients can access phase 1 trials, molecular tumour boards, reconstructive surgery and supportive care on one site.
- Sarcoma reference centre
- Early-phase trials (CLIP²)
- Precision medicine
- Radiotherapy
Pages like this
not linked directly; found by shared links- InstitutionCentre Oscar Lambret
Shares UNICANCER, Brachytherapy, IMRT / IGRT (modern external beam), Sarcomas (soft tissue, bone, GIST).
- InstitutionCentre Léon Bérard
Shares UNICANCER, Rare and paediatric cancers without markets, Comprehensive genomic profiling, Sarcomas (soft tissue, bone, GIST).
- PersonAnthony Gonçalves
Shares UNICANCER, Ovarian cancer, HR-positive / HER2-negative breast cancer.
- InstitutionTel Aviv Sourasky Medical Center
Shares Comprehensive genomic profiling, IMRT / IGRT (modern external beam), Sarcomas (soft tissue, bone, GIST), HR-positive / HER2-negative breast cancer.
- InstitutionIstanbul University Institute of Oncology
Shares Brachytherapy, Comprehensive genomic profiling, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
- InstitutionNational Institute of Oncology, Hungary
Shares Brachytherapy, Comprehensive genomic profiling, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
- TechnologyIntraoperative radiotherapy (IORT)
Shares Brachytherapy, IMRT / IGRT (modern external beam), Sarcomas (soft tissue, bone, GIST), HR-positive / HER2-negative breast cancer.
- InstitutionMasaryk Memorial Cancer Institute
Shares Brachytherapy, Comprehensive genomic profiling, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.